Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Learn how global experts are leveraging the latest data on antibody&ndash drug conjugates targeting HER2 HER3 and TROP2 to optimally manage patients with NSCLC! Download slides watch the on-demand Webcast and listen to a podcast adapted from the live expert Webinar on new developments from ELCC 2021 then review the most important data on lung cancer from ASCO 2021.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.